Article
Pharmacology & Pharmacy
Yinan Shi, Chenxin Gu, Tongtong Zhao, Yangfan Jia, Changlei Bao, Ang Luo, Qiang Guo, Ying Han, Jian Wang, Stephen M. Black, Ankit A. Desai, Haiyang Tang
Summary: Prolonged rapamycin treatment activates PDGFR signaling partially via mTORC2 inhibition. Combination therapy with rapamycin and imatinib may be a more effective strategy for the treatment of PAH, reducing proliferation and migration of hPASMCs and attenuating pulmonary hypertension in pre-clinical studies.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Dermatology
A. J. Duran-Romero, J. C. Hernandez-Rodriguez, J. Ortiz-Alvarez, J. J. Dominguez-Cruz, M. T. Monserrat-Garcia, J. Conejo-Mir Sanchez, J. Bernabeu-Wittel
Summary: Oral sirolimus shows good efficacy and safety in treating high-flow vascular malformations, with most patients experiencing partial relief and tolerating the treatment well. It can be a useful option for long-term stabilization of patients with high-flow vascular malformations.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Article
Multidisciplinary Sciences
Douglas R. Wassarman, Kondalarao Bankapalli, Leo J. Pallanck, Kevan M. Shokat
Summary: Mammalian target of rapamycin (mTOR) is a crucial factor in cell growth and metabolism, and its signaling in different tissues affects whole-organism processes. Researchers have developed selecTOR, a chemical-genetic system that restricts the activity of rapamycin analog in specific cell populations, achieving selective mTOR inhibition.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Review
Chemistry, Medicinal
Shuo Li, Jia-shu Chen, Xiangqian Li, Xiaoyi Bai, Dayong Shi
Summary: Overexpression of eIF4E is common in various solid tumors and hematologic cancers, making it a potential anti-cancer target. This review provides a detailed classification and description of the anti-cancer activities of promising compounds, concluding that MNK1/2 and eIF4E/eIF4G interaction inhibitors are superior to mTOR inhibitors for targeted therapy.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Medicine, General & Internal
Rebecca Waetzig, Marie Matthes, Johannes Leister, Gina Penkivech, Tilman Heise, Selim Corbacioglu, Gunhild Sommer
Summary: The study demonstrates that substituting Rapamycin with Torin-2 in the modified RIST protocol can reduce cell viability, induce apoptosis, and result in a broader mTOR pathway inhibition. This suggests that Torin-2 may be a promising option for treating relapsed or treatment-refractory high-risk neuroblastoma.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES
(2021)
Review
Neurosciences
Henry Querfurth, Han-Kyu Lee
Summary: mTOR is involved in regulating energy metabolism, neuronal growth, insulin signaling, and autophagy, playing both beneficial and pathogenic roles in neurodegenerative diseases. Balanced actions of mTOR complexes may have implications for Alzheimer's disease, Parkinson's disease, Huntington's disease, Frontotemporal dementia, and Amyotrophic Lateral Sclerosis. Beyond rapamycin, rapalogs with improved tolerability and delivery modes hold promise in treating age-related conditions.
MOLECULAR NEURODEGENERATION
(2021)
Article
Pharmacology & Pharmacy
Ying-hua He, Guo Tian
Summary: Autophagy plays a crucial role in renal cell carcinoma, with many autophagy-related proteins serving as prognostic markers. Researchers are exploring synthetic and phytochemical drugs targeting autophagy for RCC therapy.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, Research & Experimental
Mohamed El-Tanani, Hamdi Nsairat, Alaa A. Aljabali, Angel Serrano-Aroca, Vijay Mishra, Yachana Mishra, Gowhar A. Naikoo, Walhan Alshaer, Murtaza M. Tambuwala
Summary: The mammalian target of rapamycin (mTOR), a signalling system, is necessary for various cell proliferation activities. It recognizes PI3KAKT stress signals as a serine-threonine kinase. The abnormal regulation of mTOR pathway has been proven to be crucial in cancer growth and advancement. This review primarily discusses the normal functions of mTOR as well as its abnormal roles in cancer development.
Review
Oncology
Eunus S. Ali, Kangkana Mitra, Shamima Akter, Sarker Ramproshad, Banani Mondal, Ishaq N. Khan, Muhammad Torequl Islam, Javad Sharifi-Rad, Daniela Calina, William C. Cho
Summary: The PI3K-Akt-mTOR signaling pathway plays a crucial role in various biological activities. Targeting mTOR with rapamycin-derived compounds has proven effective in suppressing mTOR activity and reducing cancer cell growth.
CANCER CELL INTERNATIONAL
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Rachelle Durand, Janet R. Reid, Jean B. Belasco, Sphoorti Shellikeri, Juan S. Calle-Toro, Anne Marie Cahill, Abhay Srinivasan
Summary: This study retrospectively characterized changes seen on MRI of children with extensive LMs treated with sirolimus. Significant reductions in volume and signal on T2-weighted MRI were observed with sirolimus treatment, with greater decreases in volume seen in younger children and craniocervical lesions.
AMERICAN JOURNAL OF ROENTGENOLOGY
(2021)
Review
Chemistry, Medicinal
Patrik Oleksak, Eugenie Nepovimova, Zofia Chrienova, Kamil Musilek, Jiri Patocka, Kamil Kuca
Summary: Mechanistic target of rapamycin (mTOR) is a protein kinase that regulates cell functions. Dysregulation of mTOR activity is associated with various pathological conditions. Inhibition of overactivated mTOR is a rational approach for treating human diseases. Rapamycin is a natural inhibitor of mTOR with antitumor and immunosuppressive activity. Different generations of mTOR inhibitors have been developed, including rapalogs, mTOR kinase inhibitors, and dual PI3K/mTOR inhibitors. Novel inhibitors are still being developed to better understand the role of mTOR in signaling pathways and human diseases.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
(2022)
Article
Oncology
Jianya Huan, Petros Grivas, Jasmine Birch, Donna E. Hansel
Summary: The mammalian target of rapamycin (mTOR) pathway plays a crucial role in cell growth and metabolism. Dysregulation of this pathway can promote cancer growth and progression. Approximately 70% of bladder cancer (UC) cases show abnormal mTOR activity, indicating its key role in this cancer. This review highlights the importance of mTOR signaling in UC and its potential implications for future therapy. Despite extensive research on molecular alterations of the mTOR pathway in bladder cancer, there has been limited success in mTOR-targeted therapy. Further understanding of the signaling convergence onto mTOR complexes in bladder cancer may provide valuable insights for the treatment of this aggressive disease.
Article
Oncology
Sohag Chakraborty, Matthew B. Utter, Maria A. Frias, David A. Foster
Summary: This study reveals that mutations in the RB and CDKN2A genes in cancer cells lead to resistance to rapamycin, which can be reversed by restoring wild type RB or inhibiting E2F activity. This has important implications for precision medicine approaches to anti-cancer therapies.
Article
Endocrinology & Metabolism
Calum Forteath, Ify Mordi, Raid Nisr, Erika J. Gutierrez-Lara, Noor Alqurashi, Iain R. Phair, Amy R. Cameron, Craig Beall, Ibrahim Bahr, Mohapradeep Mohan, Aaron K. F. Wong, Adel Dihoum, Anwar Mohammad, Colin N. A. Palmer, Douglas Lamont, Kei Sakamoto, Benoit Viollet, Marc Foretz, Chim C. Lang, Graham Rena
Summary: Using cellular approaches and proteomics, we found that metformin therapy for diabetes alters the regulation of branched chain amino acids through the suppression of the amino acid transporter SNAT2.
MOLECULAR METABOLISM
(2023)
Article
Clinical Neurology
Marc Pawlitzki, Christopher Nelke, Melanie Korsen, Sven G. Meuth, Tobias Ruck
Summary: The study provides evidence for the use of sirolimus in treating patients with IBM, showing significant and prolonged clinical improvement without adverse effects. While no meaningful changes were observed in CD8(+) T-cell subsets, further research should explore the potential myoprotective effects of sirolimus.
EUROPEAN JOURNAL OF NEUROLOGY
(2022)
Article
Medicine, General & Internal
Yasuyoshi Morita, Masakatsu Emoto, Kentaro Serizawa, Shinya Rai, Chikara Hirase, Yoshitaka Kanai, Yasuyo Ohyama, Toshihiko Shiga, Hirokazu Tanaka, Junichi Miyatake, Yoichi Tatsumi, Takashi Ashida, Masatomo Kimura, Masafumi Ito, Itaru Matsumura
Article
Oncology
E. Togasaki, J. Takeda, K. Yoshida, Y. Shiozawa, M. Takeuchi, M. Oshima, A. Saraya, A. Iwama, K. Yokote, E. Sakaida, C. Hirase, A. Takeshita, K. Imai, H. Okumura, Y. Morishita, N. Usui, N. Takahashi, S. Fujisawa, Y. Shiraishi, K. Chiba, H. Tanaka, H. Kiyoi, K. Ohnishi, S. Ohtake, N. Asou, Y. Kobayashi, Y. Miyazaki, S. Miyano, S. Ogawa, I. Matsumura, C. Nakaseko, T. Naoe
BLOOD CANCER JOURNAL
(2017)
Article
Hematology
Jun Ishikawa, Itaru Matsumura, Tatsuya Kawaguchi, Junya Kuroda, Hirohisa Nakamae, Toshihiro Miyamoto, Ken-ichi Matsuoka, Hirohiko Shibayama, Masayuki Hino, Chikara Hirase, Tomohiko Kamimura, Takayuki Shimose, Koichi Akashi, Yuzuru Kanakura
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2018)
Article
Hematology
Masahiro Kizaki, Naoto Takahashi, Noriyoshi Iriyama, Shinichiro Okamoto, Takaaki Ono, Noriko Usui, Koiti Inokuchi, Chiaki Nakaseko, Mineo Kurokawa, Masahiko Sumi, Fumihiko Nakamura, Tatsuya Kawaguchi, Ritsuro Suzuki, Kazuhito Yamamoto, Kazunori Ohnishi, Itaru Matsumura, Tomoki Naoe, M. Kizaki, S. Mori, T. Nemoto, M. Sagawa, T. Tabayashi, M. Tokuhira, T. Tomikawa, R. Watanabe, Y. Hatta, Y. Inoue, N. Iriyama, S. Kobayashi, Y. Kobayashi, D. Kurita, D. Karigane, H. Kasahara, Y. Koda, Y. Miyakawa, K. Murakami, S. Okamoto, S. Watanuki, T. Ono, Y. Nagata, A. Takeshita, N. Takahashi, Y. Kameoka, T. Yoshioka, S. Takahashi, N. Usui, K. Dan, K. Inokuchi, K. Nakamura, D. Abe, C. Nakaseko, C. Ohwada, E. Sakaida, N. Shimizu, M. Takeuchi, S. Arai, Y. Kogure, A. Koya, Y. Masamoto, A. Masuda, K. Nakazaki, K. Toyama, Y. Hiroshima, N. Ichikawa, T. Kirihara, H. Kobayashi, I. Shimizu, M. Sumi, T. Ueki, S. Hagiwara, R. Hirai, T. Miwa, F. Nakamura, M. Nakamura, M. Takeshita, A. Tanimura, F. Hayakawa, Y. Ishikawa, H. Kiyoi, M. Murata, A. Tomita, T. Kurokawa, C. Sugimori, A. Arai, O. Miura, M. Yamamoto, K. Imai, N. Kobayashi, K. Minauchi, M. Obara, S. Ota, T. Ikezoe, M. Mori, M. Sakai, A. Taniguchi, K. Togitani, H. Hayakawa, T. Kajiguchi, S. Kamoshita, E. Otsuka, A. Nishida, M. Saburi, Y. Saburi, H. Iida, C. Kato, Y. Kojima, H. Ohashi, Y. Miyata, K. Sugimoto, H. Yamamoto, T. Yokozawa, T. Kamae, J. Kuyama, H. Mitsui, Y. Morikawa, Y. Uchida, T. Ashida, C. Hirase, K. Kawanishi, I. Matsumura, J. Miyatake, Y. Morita, T. Sano, T. Shimada, H. Tanaka, Y. Taniguchi, Y. Tatsumi, K. Yamaguchi, F. Ishida, K. Momose, H. Nakazawa, S. Nishina, H. Sakai, N. Sekiguchi, Y. Ito, K. Ohyashiki, T. Tauchi, T. Hata, Y. Imaizumi, D. Imanishi, H. Itonaga, J. Makiyama, Y. Sawayama, J. Taguchi, M. Taguchi, H. Taniguchi, G. Eguchi, M. Matsuda, N. Yamairi, N. Fukushima, K. Ozeki, A. Kohno, T. Sakura, S. Takada, T. Kobayashi, H. Sakamaki, N. Asou, T. Kawaguchi, T. Kiguchi, T. Masunari, N. Sezaki, M. Iino, K. Morinaga, K. Ikeda, K. Ogawa, H. Noji, H. Iwasaki, K. Takenaka, T. Miyamoto, H. Handa, H. Murakami, N. Tsukamoto, T. Eto, H. Henzan, Y. Kamitsuji, N. Uoshima, M. Hagihara, H. Takahashi, N. Emi, M. Okamoto, K. Kawakami, M. Waki, N. Fukuhara, H. Harigae, T. Murayama, I. Mizuno, H. Okumura, Y. Tsutsumi, K. Usuki, T. Fujisaki, Y. Maeda, Y. Suehiro, H. Suzushima, K. Yamamoto, Y. Kanakura, K. Nagasaki, H. Muto, S. Fujisawa, A. Mugitani, S. Yamasaki, Y. Adachi, T. Kamimura, Y. Takamatsu, T. Ryu, S. Chiba, K. Ohishi, K. Suzuki, D. Ogawa, H. Mihara, H. Fujita, K. Kubo, A. Yokota, C. Yoshida, S. Nakachi, T. Myojyo, A. Kitabayashi, J. Suzumiya, M. Hino, A. Wakita, T. Shibata, T. Takahashi, H. Takamatsu, K. Fujimaki, K. Tajika, M. Mita, Y. Terui, M. Ito, T. Yamane, K. Yamamoto, T. Yamauchi, Y. Kohara, C. Takebayashi, A. Inagaki, M. Tsuji, H. Shinzaki, Y. Moriuchi, M. Ishikawa, K. Miyazaki, E. Shima, N. Kinugawa
INTERNATIONAL JOURNAL OF HEMATOLOGY
(2019)
Review
Oncology
Ken Hatogai, Yuka Kato, Chikara Hirase
Summary: The study reviewed the efficacy evaluations of new drug approvals in Japan based on single-arm clinical trials, revealing an increasing trend in single-arm trial-based approvals. These approvals showed a tendency towards biomarker-related indications and hematological malignancies, with response-related outcomes as the primary endpoint.
Article
Hematology
Takahide Taniguchi, Shoko Nakayama, Hirokazu Tanaka, Shinya Rai, Chikara Hirase, Yasuyoshi Morita, Yoichi Tatsumi, Takashi Ashida, Mitsuhiro Matsuda, Shigeo Hashimoto, Itaru Matsumura
Summary: We demonstrate that the haemoglobin-platelet index (HPI) can effectively predict the prognosis of patients with diffuse large B-cell lymphoma not otherwise specified (DLBCL NOS). HPI is able to differentiate progression-free survival (PFS) and overall survival in a validation cohort, and it performs independently of other prognostic markers. Additionally, interleukin-6 (IL-6) produced by lymphoma cells is found to be involved in the development of anaemia and thrombocytopenia in DLBCL NOS patients.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Meeting Abstract
Oncology
Yuka Kato, Chikara Hirase, Ken Hatogai
JOURNAL OF CLINICAL ONCOLOGY
(2020)
Article
Medicine, General & Internal
Yasuhiro Taniguchi, Naoto Takahashi, Masatomo Miura, Chikara Hirase, Sanae Sueda, Jorge Luis Espinoza, Shinya Rai, Shoko Nakayama, Kentaro Serizawa, Takahiro Kumode, Yosaku Watatani, Yasuyoshi Morita, Hirokazu Tanaka, Itaru Matsumura
Meeting Abstract
Hematology
Yasuhito Nannya, June Takeda, Shinya Sato, Yusuke Shiozawa, Yuichi Shiraishi, Keisuke Kataoka, Kenichi Chiba, Hiroko Tanaka, Shigeru Chiba, Norio Asou, Hitoshi Kiyoi, Kiyotoshi Imai, Chikara Hirase, Nobuaki Dobashi, Toru Kiguchi, Shinji Nakao, Kazuma Ohyashiki, Yasushi Miyazaki, Tomoki Naoe, Hideki Makishima, Satoru Miyano, Kenichi Yoshida, Seishi Ogawa
Meeting Abstract
Hematology
Y. Nannya, J. Takeda, Y. Shiozawa, Y. Shiraishi, Y. Okuno, K. Kataoka, K. Chiba, H. Tanaka, M. Sanada, S. Chiba, N. Asou, H. Kiyoi, K. Imai, C. Hirase, N. Dobashi, T. Kiguchi, S. Nakao, K. Ohyashiki, Y. Miyazaki, T. Naoe, H. Makishima, S. Miyano, K. Yoshida, S. Ogawa
Meeting Abstract
Hematology
June Takeda, Yusuke Shiozawa, Yuichi Shiraishi, Yusuke Okuno, Keisuke Kataoka, Kenichi Chiba, Hiroko Tanaka, Masashi Sanada, Shigeru Chiba, Norio Asou, Hitoshi Kiyoi, Kiyotoshi Imai, Chikara Hirase, Nobuaki Dobashi, Toru Kiguchi, Yasushi Miyazaki, Tomoki Naoe, Hideki Makishima, Satoru Miyano, Seishi Ogawa, Kenichi Yoshida
Meeting Abstract
Hematology
C. Nakaseko, J. Takeda, E. Togasaki, K. Yoshida, Y. Shiozawa, M. Takeuchi, M. Oshima, A. Saraya, A. Iwama, K. Yokote, E. Sakaida, C. Hirase, A. Takeshita, K. Imai, H. Okumura, Y. Morishita, N. Usui, N. Takahashi, S. Fujisawa, Y. Shiraishi, K. Chiba, H. Tanaka, H. Kiyoi, K. Ohnishi, S. Ohtake, N. Asou, Y. Kobayashi, Y. Miyazaki, S. Miyano, S. Ogawa, I. Matsumura, T. Naoe
Meeting Abstract
Hematology
J. Takeda, K. Yoshida, H. Makishima, T. Yoshizato, Y. Shiozawa, H. Suzuki, Y. Shiraishi, Y. Okuno, A. Kon, K. Kataoka, K. Chiba, H. Tanaka, M. Sanada, M. Sakata-Yanagimoto, N. Obara, T. Nakamaki, K. Ishiyama, A. Hangaishi, S. Chiba, H. Mori, N. Asou, H. Kiyoi, C. Hirase, K. Imai, N. Dobashi, T. Kiguchi, Y. Miyazaki, T. Naoe, S. Miyano, K. Usuki, S. Miyawaki, Y. Kamatani, Y. Momozawa, M. Kubo, Y. Suzuki, Y. Kawai, M. Nagasaki, M. A. Sekeres, C. Polprasert, J. P. Maciejewski, S. Ogawa
Meeting Abstract
Hematology
June Takeda, Kenichi Yoshida, Hideki Makishima, Tetsuichi Yoshizato, Yusuke Shiozama, Yuichi Shiraishi, Yusuke Okuno, Ayana Kon, Yasunobu Nagata, Keisuke Kataoka, Kenichi Chiba, Hiroko Tanaka, Masashi Sanada, Mamiko Sakata-Yanagimoto, Naoshi Obara, Tsuyoshi Nakamaki, Ken Ishiyama, Akira Haigaishi, Shigeru Chiba, Hiraku Mori, Norio Asou, Hitoshi Kiyoi, Chikara Hirase, Kiyotoshi Imai, Nobuaki Dobashi, Toru Kiguchi, Yasushi Miyazaki, Tomoki Naoe, Satoru Miyano, Kensuke Usuki, Shuichi Miyawaki, Yoichiro Kamatani, Yukihide Momozawa, Michiaki Kubo, Chantana Polprasert, Jaroslaw P. Maciejewski, Seishi Ogawa
Meeting Abstract
Hematology
Yasunobu Nagata, Hiromichi Suzuki, Vera Grossmann, Genta Nagae, Yusuke Okuno, Ulrike Bacher, Susanne Schnittger, Yusuke Shiozawa, Tetsuichi Yoshizato, Tamara Alpermann, Kenichi Yoshida, Keisuke Kataoka, Niroshan Nadarajah, Andreas Roller, Yuichi Shiraishi, Kenichi Chiba, Hiroko Tanaka, Alexander Kohlmann, Claudia Haferlach, Tsutomu Sato, Chikara Hirase, Nobuaki Dobashi, Toru Kiguchi, Shigeru Chiba, Shigeki Ohtake, Hitoshi Kiyoi, Yukio Kobayashi, Tomoki Naoe, Satoru Miyano, Wolfgang Kern, Hideki Makishima, Hiroyuki Aburatani, Yasushi Miyazaki, Torsten Haferlach, Seishi Ogawa